Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma

Thrombosis and Haemostasis

Volumn 102, Issue 5, 2009, Pages 1001-1006

  Dempfle, Carl Erik ^a   Zharkowa, Ulyana ^a   Elmas, Elif ^a   Ahmad Nejad, Parviz ^a   Neumaier, Michael ^a   Borggrefe, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Fondaparinux; Heparins; Heptest; LMWH; Monitoring; Pregnancy

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CERTOPARIN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; FRAGMIN P; HEPARIN; HEPARIN RATIOPHARM; MONOEMBOLEX; NADROPARIN; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; CALIBRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MONITORING; FEMALE; HUMAN; INTERMETHOD COMPARISON; MATERNAL PLASMA; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; PRIORITY JOURNAL;

BLOOD COAGULATION TESTS; CALIBRATION; CHROMOGENIC COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FACTOR XA; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PARTIAL THROMBOPLASTIN TIME; POLYSACCHARIDES; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD;

EID: 70449587447     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-09-0560     Document Type: Article

References (26)

1. Deruelle P, Coulon C. The use of low-molecularweight heparins in pregnancy - how safe are they? Curr Opin Obstet Gynecol 2007; 19: 573-577.
2. McColl MD, Greer IA. Low-molecular-weight heparin for the prevention and treatment of venous thromboembolism in pregnancy. Curr Opin Pulm Med 2004; 10: 371-375. (Pubitemid 39099932)
3. Hills FA, Abrahams VM, Gonzalez-Timon B, et al. Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod 2006; 12: 237-243. (Pubitemid 43779075)
4. Ganapathy R, Whitley GS, Cartwright JE, et al. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod 2007; 22: 2523-2527. (Pubitemid 47296606)
5. Kawamata K, Neki R, Yamanaka K, et al. Risks and pregnancy outcome in women with prosthetic mechanical heart valve replacement. Circ J 2007; 71: 211-213. (Pubitemid 46182694)
6. Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 2004;92:747-751. (Pubitemid 39386701)
7. Casele HL. The use of unfractionated heparin and low molecular weight heparins in pregnancy. Clin Obstet Gynecol 2006; 49: 895-905. (Pubitemid 44691212)
8. Campbell PJ, Tirvengadum MA, Pickering W, et al. HEPTEST: a suitable method for monitoring heparin during pregnancy. Clin Lab Haematol 1999; 21: 193-199. (Pubitemid 29327341)
9. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119: 122S-131S.
10. Yin ET, Wessler S, Butler JV. Plasma heparin: a unique, practical, submicrogram-sensitive assay. J Lab Clin Med 1973; 81: 298-310.
11. Yin ET, Denson KW. Letter: Procedure for the determination of heparin. Thromb Diath Haemorrh 1975; 33: 393-395.
12. Kitchen S, Iampietro R, Woolley AM, et al. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999; 82: 1289-1293. (Pubitemid 29473794)
13. Abbate R, Gori AM, Farsi A, et al. Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol 1998; 82: 33L-36L. (Pubitemid 28413663)
14. Bara L, Combe-Tamzali S, Conard J, et al. Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clotting test (Heptest). Haemostasis 1987; 17: 127-133.
15. Harenberg J. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins. J Mal Vasc 1987; 12 (Suppl B): 68-70.
16. Abildgaard U, Norrheim L, Larsen AE, et al. Monitoring therapy with LMW heparin: a comparison of three chromogenic substrate assays and the Heptest clotting assay. Haemostasis 1990; 20: 193-203. (Pubitemid 20244665)
17. Bara L, Mardiguian J, Samama M. In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thromb Res 1990; 57: 585-592.
18. Walenga JM, Hoppensteadt D, Fareed J. Laboratory monitoring of the clinical effects of low molecular weight heparins. Thromb Res (Suppl) 1991; 14: 49-62.
19. Chunilal SD, Young E, Johnston MA, et al. The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost 2002; 87: 92-97. (Pubitemid 34092581)
20. Abou-Nassar K, Kovacs MJ, Kahn SR, et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thromb Haemost 2007; 98: 163-171. (Pubitemid 47074192)
21. Norris LA, Bonnar J, Smith MP, et al. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. Thromb Haemost 2004; 92: 791-796. (Pubitemid 39386706)
22. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 627S-644S. (Pubitemid 39297966)
23. Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004; 148: 582-589.
24. Woodhams B, Girardot O, Blanco MJ, Colesse G, Gourmelin Y. Stability of coagulation proteins in frozen plasma. Blood Coagul Fibrinolysis 2001; 12: 229-236. (Pubitemid 32575155)
25. Alesci S, Borggrefe M, Dempfle CE. Effect of freezing method and storage at -20 degrees C and -70 degrees C on prothrombin time, aPTT and plasma fibrinogen levels. Thromb Res 2009; 124: 121-126.
26. Akerblom O, Bremme K, Dackland AL, et al. Freezing technique and quality of fresh-frozen plasma. Infusionsther Transfusionsmed 1992; 19: 283-287. (Pubitemid 23055865)